Related Story

Akero's Efruxifermin Reverses Liver Scarring in MASH Patients, Boosting $AKRO and $ETNB Stocks
Akero Therapeutics Inc. ($AKRO) has reported promising results from its Phase 2b SYMMETRY study, demonstrating that its drug efruxifermin significantly reversed liver scarring in patients with compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH). The study showed a 24-point difference in liver fibrosis improvement at 96 weeks, with 39% of patients on a 50-mg dose of efruxifermin achieving a clinically meaningful reduction in liver fibrosis compared to 15% on placebo. The results were statistically significant under both completer and intent-to-treat (ITT) analyses. The positive outcome has led to a surge in Akero's stock, with shares trading 100% higher pre-market. The success of efruxifermin, an FGF21 analog, is also seen as a positive development for other companies in the same class, such as 89bio Inc. ($ETNB), which is also developing an FGF21 analog, pegozafermin, for similar indications. 89bio's stock rose to $12, and Cantor expects $ETNB shares to reach $15, representing over 100% upside, based on the findings from the trial. 89bio is currently conducting three separate Phase 3 trials for pegozafermin, each targeting market opportunities exceeding $1 billion in the U.S. alone.
Proposed Market

Highest stock price increase percentage among FGF21 analog developers by Q1 2025 end?
Description
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Market Options
Related Polymarket Markets
No similar markets found
This could indicate a unique market opportunity that hasn't been explored yet.